Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

This phase II trial examined the addition of ramucirumab, a vascular endothelial growth factor receptor-2 monoclonal antibody, to mFOLFOX6 as front-line therapy for patients with advanced gastric/GEJ or esophageal adenocarcinoma. A survival benefit was not observed in the ITT population, but an expl...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Yoon, H.H., Bendell, J.C., Braiteh, F.S., Firdaus, I., Philip, P.A., Cohn, A.L., Lewis, N., Anderson, D.M., Arrowsmith, E., Schwartz, J.D., Gao, L., Hsu, Y., Xu, Y., Ferry, D., Alberts, S.R., Wainberg, Z.A.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
gastrointestinal tumor
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360144/
https://ncbi.nlm.nih.gov/pubmed/27765757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw423
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki